S&P 500   5,069.53
DOW   39,069.23
QQQ   436.55
Is CRISPR Therapeutics the NVIDIA of gene editing?
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 Chinese stocks poised for rebound
4 stocks benefitting from NVIDIA's explosive growth
Critical asset just had biggest fall on record (Ad)
These 2 carnivore dining stocks gaining on the Ozempic craze
This healthcare stock making a buzz with 160% growth
Critical asset just had biggest fall on record (Ad)
First it was Tyson stock, now this food company is set to rally
How major US stock indexes fared Monday, 2/26/2024
S&P 500   5,069.53
DOW   39,069.23
QQQ   436.55
Is CRISPR Therapeutics the NVIDIA of gene editing?
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 Chinese stocks poised for rebound
4 stocks benefitting from NVIDIA's explosive growth
Critical asset just had biggest fall on record (Ad)
These 2 carnivore dining stocks gaining on the Ozempic craze
This healthcare stock making a buzz with 160% growth
Critical asset just had biggest fall on record (Ad)
First it was Tyson stock, now this food company is set to rally
How major US stock indexes fared Monday, 2/26/2024
S&P 500   5,069.53
DOW   39,069.23
QQQ   436.55
Is CRISPR Therapeutics the NVIDIA of gene editing?
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 Chinese stocks poised for rebound
4 stocks benefitting from NVIDIA's explosive growth
Critical asset just had biggest fall on record (Ad)
These 2 carnivore dining stocks gaining on the Ozempic craze
This healthcare stock making a buzz with 160% growth
Critical asset just had biggest fall on record (Ad)
First it was Tyson stock, now this food company is set to rally
How major US stock indexes fared Monday, 2/26/2024
S&P 500   5,069.53
DOW   39,069.23
QQQ   436.55
Is CRISPR Therapeutics the NVIDIA of gene editing?
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 Chinese stocks poised for rebound
4 stocks benefitting from NVIDIA's explosive growth
Critical asset just had biggest fall on record (Ad)
These 2 carnivore dining stocks gaining on the Ozempic craze
This healthcare stock making a buzz with 160% growth
Critical asset just had biggest fall on record (Ad)
First it was Tyson stock, now this food company is set to rally
How major US stock indexes fared Monday, 2/26/2024
NASDAQ:LIVN

LivaNova (LIVN) Stock Price, News & Analysis

$55.97
-1.15 (-2.01%)
(As of 02/26/2024 ET)
Today's Range
$55.93
$57.46
50-Day Range
$48.60
$57.12
52-Week Range
$40.26
$59.86
Volume
434,974 shs
Average Volume
459,531 shs
Market Capitalization
$3.02 billion
P/E Ratio
174.91
Dividend Yield
N/A
Price Target
$63.40

LivaNova MarketRank™ Stock Analysis

Analyst Rating
Hold
2.40 Rating Score
Upside/​Downside
13.3% Upside
$63.40 Price Target
Short Interest
Bearish
4.29% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.72mentions of LivaNova in the last 14 days
Based on 34 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
8.31%
From $3.01 to $3.26 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.87 out of 5 stars

Medical Sector

724th out of 942 stocks

Electromedical Equipment Industry

15th out of 19 stocks


LIVN stock logo

About LivaNova Stock (NASDAQ:LIVN)

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. It also engages in research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.

LIVN Stock Price History

LIVN Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Mizuho Upgrades LivaNova (LIVN)
LivaNova (NASDAQ:LIVN) Shares Gap Up on Strong Earnings
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
LivaNova (LIVN) Q4 Earnings and Revenues Top Estimates
LivaNova Reports Fourth-Quarter and Full-Year 2023 Results
Here's what to expect from Livanova's earnings report
LivaNova (NASDAQ:LIVN) Upgraded to Buy at Mizuho
LIVN Mar 2024 55.000 put
PRIMECAP Management Bolsters Stake in LivaNova PLC
Livanova names J&J veteran Vladimir Makatsaria as CEO
LivaNova Names Vladimir Makatsaria Chief Executive
LivaNova names Vladimir Makatsaria as CEO
See More Headlines
Receive LIVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LivaNova and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/21/2024
Today
2/26/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Electromedical equipment
Sub-Industry
N/A
Current Symbol
NASDAQ:LIVN
Employees
2,900
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$63.40
High Stock Price Target
$72.00
Low Stock Price Target
$52.00
Potential Upside/Downside
+11.8%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
5 Analysts

Profitability

Net Income
$17.60 million
Pretax Margin
-7.04%

Debt

Sales & Book Value

Annual Sales
$1.15 billion
Cash Flow
$4.22 per share
Book Value
$23.72 per share

Miscellaneous

Free Float
53,769,000
Market Cap
$3.02 billion
Optionable
Optionable
Beta
0.86
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. William A. Kozy (Age 72)
    Chairman of Board & Interim CEO
    Comp: $185k
  • Mr. Alex Shvartsburg (Age 53)
    Chief Financial Officer
    Comp: $852.2k
  • Ms. Trui Hebbelinck (Age 52)
    Chief Human Resources Officer
    Comp: $731.41k
  • Mr. Badri Amurthur
    Chief Technology Officer
  • Lindsey Little
    Senior Director of Investor Relations
  • Mr. Michael Hutchinson (Age 53)
    Senior VP, Chief Legal Officer & Company Secretary
  • Deanna Wilke
    Vice President of Corporate Communications
  • Mr. Matthew Joseph Dodds III
    Senior Vice President of Corporate Development & IT
  • Dr. Bryan D. Olin Ph.D. (Age 57)
    Senior VP & Head of Product Development - Neuromodulation
  • Mr. Ryan Miller
    President of Advanced Circulatory Support














LIVN Stock Analysis - Frequently Asked Questions

Should I buy or sell LivaNova stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for LivaNova in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" LIVN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LIVN, but not buy additional shares or sell existing shares.
View LIVN analyst ratings
or view top-rated stocks.

What is LivaNova's stock price target for 2024?

5 Wall Street research analysts have issued 1 year target prices for LivaNova's shares. Their LIVN share price targets range from $52.00 to $72.00. On average, they expect the company's stock price to reach $63.40 in the next twelve months. This suggests a possible upside of 13.3% from the stock's current price.
View analysts price targets for LIVN
or view top-rated stocks among Wall Street analysts.

How have LIVN shares performed in 2024?

LivaNova's stock was trading at $51.74 at the start of the year. Since then, LIVN shares have increased by 8.2% and is now trading at $55.97.
View the best growth stocks for 2024 here
.

When is LivaNova's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our LIVN earnings forecast
.

How were LivaNova's earnings last quarter?

LivaNova PLC (NASDAQ:LIVN) posted its earnings results on Wednesday, February, 21st. The company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.77 by $0.10. The company had revenue of $310.10 million for the quarter, compared to the consensus estimate of $287.65 million. LivaNova had a net margin of 1.53% and a trailing twelve-month return on equity of 12.23%. LivaNova's revenue was up 12.8% on a year-over-year basis. During the same period in the prior year, the firm earned $0.81 EPS.

What guidance has LivaNova issued on next quarter's earnings?

LivaNova issued an update on its FY24 earnings guidance on Wednesday, February, 21st. The company provided earnings per share guidance of $2.95-3.05 for the period, compared to the consensus estimate of $2.99.

What is Damien McDonald's approval rating as LivaNova's CEO?

47 employees have rated LivaNova Chief Executive Officer Damien McDonald on Glassdoor.com. Damien McDonald has an approval rating of 77% among the company's employees.

What other stocks do shareholders of LivaNova own?
Who are LivaNova's major shareholders?

LivaNova's stock is owned by many different retail and institutional investors. Top institutional investors include Primecap Management Co. CA (10.75%), Vanguard Group Inc. (3.29%), Dimensional Fund Advisors LP (2.31%), Greenlight Capital Inc. (2.28%), Barclays PLC (1.80%) and Victory Capital Management Inc. (1.54%). Insiders that own company stock include Alfred J Novak, Damien Mcdonald, Daniel Jeffrey Moore and Marco Dolci.
View institutional ownership trends
.

How do I buy shares of LivaNova?

Shares of LIVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LIVN) was last updated on 2/27/2024 by MarketBeat.com Staff